Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

IMPALA Phase 3 Study of Molgradex Does Not Meet Primary Endpoint

americanpharmaceuticalreviewJune 14, 2019

Tag: study , IMPALA , Molgradex

PharmaSources Customer Service